J&J in Talks to Sell Orthopedics Unit to Apollo for $20 Billion

Key Facts

1Johnson & Johnson is in talks to sell its DePuy Synthes hips-and-knees business to Apollo Global Management.

2The potential deal is valued at approximately $20 billion as the company aims to focus on higher-growth areas.

In a move reflecting the trend of major healthcare firms restructuring their investment portfolios, Johnson & Johnson is in talks to divest its DePuy Synthes unit. According to reports, the potential deal involves the hips-and-knees business, with the company negotiating with private equity firm Apollo Global Management. This step aims to streamline operations and reallocate resources toward higher-growth medical sectors in a deal valued at approximately $20 billion.

This news comes as major corporations seek to enhance market value by shedding legacy assets, a strategy evident in JNJ's current approach. Per market data, JNJ shares stood at $265.58 (close September 11, 2026), having reached a session high of $270.385. This potential divestiture of the orthopedics unit is a strategic move to decouple from slower-growth segments compared to modern medical innovations.

Investors should watch for support levels near $265.25, the daily low recorded at the close of September 11, 2026. With no immediate catalysts in the upcoming economic calendar specifically targeting the healthcare sector, focus will remain on official announcements regarding the progress of negotiations with Apollo. A successful deal could mark a significant turning point in the company's financial trajectory.